United Therapeutics Corp (UTHR)
301.42
-6.58
(-2.14%)
USD |
NASDAQ |
May 09, 16:00
301.01
-0.41
(-0.14%)
After-Hours: 20:00
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 13.60B |
| 52 Week High (Daily) | Upgrade |
| 52 Week Low (Daily) | Upgrade |
| All-Time High (Daily) | Upgrade |
| Year to Date Total Returns (Daily) | Upgrade |
| 1 Month Total Returns (Daily) | Upgrade |
| 1 Year Total Returns (Daily) | 13.29% |
| Valuation | |
| PE Ratio | 12.03 |
| PE Ratio (Forward) | Upgrade |
| PS Ratio | 4.857 |
| Price to Book Value | 1.997 |
| EV to EBITDA | Upgrade |
| Dividend | |
|---|---|
| Dividend | -- |
| Dividend Yield (Forward) | Upgrade |
| Financials | |
| Revenue (5 Year Growth) | Upgrade |
| Revenue (Quarterly YoY Growth) | Upgrade |
| EPS Diluted (5 Year Growth) | Upgrade |
| EPS Diluted (Quarterly YoY Growth) | Upgrade |
| Debt to Equity Ratio | 0.0294 |
| Return on Equity | Upgrade |
| Return on Assets | Upgrade |
| Risk | |
| Beta (5Y) | Upgrade |
| Max Drawdown (5Y) | 40.79% |
Profile
Edit
| United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. In addition, it is developing a pipeline of projects that includes new indications and delivery devices for existing products and new products to treat PAH and other conditions. |
| URL | https://www.unither.com |
| Investor Relations URL | https://ir.unither.com/ |
| HQ State/Province | Maryland |
| Sector | Health Care |
| Industry | Biotechnology |
| Next Earnings Release | Jul. 31, 2025 (est.) |
| Last Earnings Release | Apr. 30, 2025 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |
Ratings
Profile
Edit
| United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. In addition, it is developing a pipeline of projects that includes new indications and delivery devices for existing products and new products to treat PAH and other conditions. |
| URL | https://www.unither.com |
| Investor Relations URL | https://ir.unither.com/ |
| HQ State/Province | Maryland |
| Sector | Health Care |
| Industry | Biotechnology |
| Next Earnings Release | Jul. 31, 2025 (est.) |
| Last Earnings Release | Apr. 30, 2025 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |